JP6753933B2 - 線維化の治療 - Google Patents

線維化の治療 Download PDF

Info

Publication number
JP6753933B2
JP6753933B2 JP2018531325A JP2018531325A JP6753933B2 JP 6753933 B2 JP6753933 B2 JP 6753933B2 JP 2018531325 A JP2018531325 A JP 2018531325A JP 2018531325 A JP2018531325 A JP 2018531325A JP 6753933 B2 JP6753933 B2 JP 6753933B2
Authority
JP
Japan
Prior art keywords
fibrosis
expression
antibody
fibroblasts
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018531325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502689A5 (https=
JP2019502689A (ja
Inventor
アレクサンダー クック，ステュアート
アレクサンダー クック，ステュアート
シェイファー，セバスチャン
Original Assignee
シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド
ナショナル ユニヴァーシティー オブ シンガポール
ナショナル ユニヴァーシティー オブ シンガポール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55274842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6753933(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド, ナショナル ユニヴァーシティー オブ シンガポール, ナショナル ユニヴァーシティー オブ シンガポール filed Critical シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド
Publication of JP2019502689A publication Critical patent/JP2019502689A/ja
Publication of JP2019502689A5 publication Critical patent/JP2019502689A5/ja
Application granted granted Critical
Publication of JP6753933B2 publication Critical patent/JP6753933B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018531325A 2015-12-16 2016-12-16 線維化の治療 Active JP6753933B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522186.4A GB201522186D0 (en) 2015-12-16 2015-12-16 Treatment of fibrosis
GB1522186.4 2015-12-16
PCT/EP2016/081430 WO2017103108A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020139045A Division JP7102474B2 (ja) 2015-12-16 2020-08-20 線維化の治療

Publications (3)

Publication Number Publication Date
JP2019502689A JP2019502689A (ja) 2019-01-31
JP2019502689A5 JP2019502689A5 (https=) 2019-10-31
JP6753933B2 true JP6753933B2 (ja) 2020-09-09

Family

ID=55274842

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018531325A Active JP6753933B2 (ja) 2015-12-16 2016-12-16 線維化の治療
JP2020139045A Active JP7102474B2 (ja) 2015-12-16 2020-08-20 線維化の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020139045A Active JP7102474B2 (ja) 2015-12-16 2020-08-20 線維化の治療

Country Status (24)

Country Link
US (16) US10035852B2 (https=)
EP (7) EP3428187A1 (https=)
JP (2) JP6753933B2 (https=)
KR (2) KR20240152973A (https=)
CN (2) CN116036284A (https=)
AU (7) AU2016369407B2 (https=)
CA (1) CA3007750A1 (https=)
CY (1) CY1120950T1 (https=)
DK (1) DK3298040T3 (https=)
ES (1) ES2692773T3 (https=)
GB (1) GB201522186D0 (https=)
HR (1) HRP20181692T1 (https=)
HU (1) HUE041433T2 (https=)
LT (1) LT3298040T (https=)
NZ (1) NZ744307A (https=)
PL (1) PL3298040T3 (https=)
PT (1) PT3298040T (https=)
RS (1) RS57894B1 (https=)
SG (2) SG10201908380TA (https=)
SI (1) SI3298040T1 (https=)
SM (1) SMT201800601T1 (https=)
TR (1) TR201815415T4 (https=)
WO (1) WO2017103108A1 (https=)
ZA (1) ZA201803727B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020189879A (ja) * 2015-12-16 2020-11-26 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 線維化の治療

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180186871A1 (en) * 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
EP3914621A1 (en) 2019-01-21 2021-12-01 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
GB201902419D0 (en) * 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
BR112021021921A2 (pt) * 2019-05-03 2021-12-28 Nat Univ Singapore Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
US12343336B2 (en) 2019-08-05 2025-07-01 Novocure Gmbh Increasing cancer cells' sensitivity to tumor treating fields (TTFields) by inhibiting IL11 activity
KR102270700B1 (ko) * 2019-11-01 2021-06-30 한국과학기술연구원 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
EP4198055A4 (en) * 2020-08-13 2024-08-28 Sunshine Lake Pharma Co., Ltd. IL-11 ANTIBODY AND ITS USE
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
JP2024512279A (ja) 2021-02-26 2024-03-19 バイエル アクチェンゲゼルシャフト 異常子宮出血の処置における使用のためのｉｌ－１１又はｉｌ－１１ｒａの阻害剤
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
MX2024002611A (es) 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
CN115068442A (zh) * 2021-09-13 2022-09-20 荣灿生物医药技术(上海)有限公司 核酸的纳米颗粒组合物、其制备方法和用途
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
CN115414346B (zh) * 2022-08-29 2023-09-29 湖南复瑞生物医药技术有限责任公司 一种应用胺碘酮构造肺纤维化模型的方法
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
CN120518761B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN117085137A (zh) * 2023-10-10 2023-11-21 上海交通大学医学院附属第九人民医院 Il-11抑制剂及其在抗瘢痕治疗中的应用
CN117964734B (zh) * 2024-03-04 2025-12-26 四川大学 一种重组人白介素-11突变体及其与化学分子偶联缀合物和其制备方法与应用
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
EP1566440A3 (en) 1994-12-22 2005-10-19 Genetics Institute, Inc. Human Interleukin-11 Receptor
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
GB9721961D0 (en) 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
WO2000078336A1 (en) * 1999-06-21 2000-12-28 Genetics Institute, Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
GB0021668D0 (en) 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
WO2003049693A2 (en) 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
WO2004024125A1 (en) 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
JP2007537716A (ja) 2003-12-16 2007-12-27 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション サイトカイン結合ドメイン
EP1720562A4 (en) 2004-01-15 2009-10-28 Scios Inc METHOD FOR TREATING CARDIAL REMODELING AFTER MYOCARDIAL DAMAGE
WO2005098041A2 (en) 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Detection and treatment of fibrotic disorders
ATE399868T1 (de) 2004-08-27 2008-07-15 Conaris Res Inst Ag Optimierte nukleotidsequenzen die für sgp130 kodieren
EP1957097A1 (en) 2005-12-06 2008-08-20 Wyeth a Corporation of the State of Delaware Interleukin-11 compositions and methods of use
MX352516B (es) 2006-07-05 2017-04-06 Fibrotech Therapeutics Pty Ltd Compuestos terapeuticos.
JP5191393B2 (ja) * 2006-10-27 2013-05-08 国立大学法人大阪大学 インターロイキン１１の心疾患治療薬としての利用
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US8182814B2 (en) * 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
JP5330398B2 (ja) 2007-10-26 2013-10-30 シーエスエル、リミテッド サイトカインムテイン
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
CN117843785A (zh) * 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
CN105497893B (zh) 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
NL2020093B1 (en) 2017-12-15 2019-06-25 Stahl Int B V Process for producing aqueous polyurethane dispersions in a continuous manner; apparatus suitable for performing such a process; and products obtained by said process
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020189879A (ja) * 2015-12-16 2020-11-26 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 線維化の治療
JP7102474B2 (ja) 2015-12-16 2022-07-19 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド 線維化の治療

Also Published As

Publication number Publication date
SG11201804836RA (en) 2018-07-30
AU2018229485A1 (en) 2018-10-04
EP3431498A1 (en) 2019-01-23
HRP20181692T1 (hr) 2018-12-14
GB201522186D0 (en) 2016-01-27
US20180362639A1 (en) 2018-12-20
AU2018229484A1 (en) 2018-10-04
AU2018229484B9 (en) 2019-09-12
US20180362634A1 (en) 2018-12-20
CN116036284A (zh) 2023-05-02
HUE041433T2 (hu) 2019-05-28
US10865239B2 (en) 2020-12-15
US10106603B2 (en) 2018-10-23
AU2018229487B2 (en) 2019-08-08
US20180362638A1 (en) 2018-12-20
EP3298040A1 (en) 2018-03-28
KR20180097645A (ko) 2018-08-31
SG10201908380TA (en) 2019-11-28
JP7102474B2 (ja) 2022-07-19
US20210188962A1 (en) 2021-06-24
CY1120950T1 (el) 2019-12-11
AU2018229485B2 (en) 2019-08-08
US10870697B2 (en) 2020-12-22
EP3428187A1 (en) 2019-01-16
AU2018229486B2 (en) 2019-08-08
EP3298040B1 (en) 2018-08-01
AU2016369407B2 (en) 2018-09-13
US20180362633A1 (en) 2018-12-20
DK3298040T3 (en) 2018-11-05
US10894825B2 (en) 2021-01-19
LT3298040T (lt) 2018-12-10
AU2018229486A1 (en) 2018-10-04
KR102720360B1 (ko) 2024-10-22
ZA201803727B (en) 2019-03-27
PL3298040T3 (pl) 2019-07-31
US20180371078A1 (en) 2018-12-27
US10894827B2 (en) 2021-01-19
NZ744307A (en) 2019-03-29
WO2017103108A1 (en) 2017-06-22
AU2016369407A1 (en) 2018-08-02
JP2020189879A (ja) 2020-11-26
US20240360211A1 (en) 2024-10-31
TR201815415T4 (tr) 2018-11-21
US20180362635A1 (en) 2018-12-20
KR20240152973A (ko) 2024-10-22
ES2692773T3 (es) 2018-12-05
US10035852B2 (en) 2018-07-31
EP3428188A1 (en) 2019-01-16
AU2018229483A1 (en) 2018-10-04
SI3298040T1 (sl) 2019-01-31
JP2019502689A (ja) 2019-01-31
RS57894B1 (sr) 2019-01-31
AU2018229483B2 (en) 2019-08-08
US10865240B2 (en) 2020-12-15
US20180265579A1 (en) 2018-09-20
AU2018229484B2 (en) 2019-08-08
AU2018229482A1 (en) 2018-10-04
US10889642B2 (en) 2021-01-12
US20180362636A1 (en) 2018-12-20
US20190002553A1 (en) 2019-01-03
US20180362641A1 (en) 2018-12-20
US10865241B2 (en) 2020-12-15
US20170174759A1 (en) 2017-06-22
US10899832B2 (en) 2021-01-26
CN108495861B (zh) 2023-01-10
CN108495861A (zh) 2018-09-04
EP3431499A1 (en) 2019-01-23
AU2018229487A1 (en) 2018-10-04
EP3431500A1 (en) 2019-01-23
AU2018229482B2 (en) 2019-08-08
HK1254287A1 (zh) 2019-07-19
US10870696B2 (en) 2020-12-22
US10822405B2 (en) 2020-11-03
PT3298040T (pt) 2018-11-13
CA3007750A1 (en) 2017-06-22
US10927169B2 (en) 2021-02-23
US11939374B2 (en) 2024-03-26
EP3428186A1 (en) 2019-01-16
SMT201800601T1 (it) 2019-01-11
US10894826B2 (en) 2021-01-19
US20180371077A1 (en) 2018-12-27
US20180362637A1 (en) 2018-12-20
US20180362640A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
JP7102474B2 (ja) 線維化の治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180803

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20180803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190918

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190918

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200820

R150 Certificate of patent or registration of utility model

Ref document number: 6753933

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250